Literature DB >> 16630891

A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.

Pablo Rodriguez-Viciana1, Juan Oses-Prieto, Alma Burlingame, Mike Fried, Frank McCormick.   

Abstract

Ras family GTPases (RFGs) are known to share many regulatory and effector proteins. How signaling and biological specificity is achieved is poorly understood. Using a proteomics approach, we have identified a complex comprised of Shoc2/Sur-8 and the catalytic subunit of protein phosphatase 1 (PP1c) as a highly specific M-Ras effector. M-Ras targets Shoc2-PP1c to stimulate Raf activity by dephosphorylating the S259 inhibitory site of Raf proteins bound to other molecules of M-Ras or Ras. Therefore, distinct RFGs, through independent effectors, can regulate different steps in the activation of Raf kinases. Shoc2 function is essential for activation of the MAPK pathway by growth factors. Furthermore, in tumor cells with Ras gene mutations, inhibition of Shoc2 expression inhibits MAPK, but not PI3K activity. We propose that the Shoc2-PP1c holoenzyme provides an attractive therapeutic target for inhibition of the MAPK pathway in cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630891     DOI: 10.1016/j.molcel.2006.03.027

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  96 in total

Review 1.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

2.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

3.  Shoc2-tranduced ERK1/2 motility signals--Novel insights from functional genomics.

Authors:  Myoungkun Jeoung; Eun Ryoung Jang; Jinpeng Liu; Chi Wang; Eric C Rouchka; Xiaohong Li; Emilia Galperin
Journal:  Cell Signal       Date:  2016-02-11       Impact factor: 4.315

Review 4.  The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease.

Authors:  HyeIn Jang; Payton Stevens; Tianyan Gao; Emilia Galperin
Journal:  FEBS J       Date:  2020-07-06       Impact factor: 5.542

5.  Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

Authors:  Vladimir Beljanski; Christian Knaak; Yan Zhuang; Charles D Smith
Journal:  Invest New Drugs       Date:  2010-05-18       Impact factor: 3.850

6.  Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein.

Authors:  Tilman Brummer; Mark Larance; Maria Teresa Herrera Abreu; Ruth J Lyons; Paul Timpson; Christoph H Emmerich; Emmy D G Fleuren; Gillian M Lehrbach; Daniel Schramek; Michael Guilhaus; David E James; Roger J Daly
Journal:  EMBO J       Date:  2008-09-03       Impact factor: 11.598

Review 7.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

8.  Enhanced large conductance K+ channel activity contributes to the impaired myogenic response in the cerebral vasculature of Fawn Hooded Hypertensive rats.

Authors:  Mallikarjuna R Pabbidi; Olga Mazur; Fan Fan; Jerry M Farley; Debebe Gebremedhin; David R Harder; Richard J Roman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

9.  The scaffold protein Shoc2/SUR-8 accelerates the interaction of Ras and Raf.

Authors:  Rie Matsunaga-Udagawa; Yoshihisa Fujita; Sayaka Yoshiki; Kenta Terai; Yuji Kamioka; Etsuko Kiyokawa; Katsuyuki Yugi; Kazuhiro Aoki; Michiyuki Matsuda
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

10.  Learning transcriptional regulatory networks from high throughput gene expression data using continuous three-way mutual information.

Authors:  Weijun Luo; Kurt D Hankenson; Peter J Woolf
Journal:  BMC Bioinformatics       Date:  2008-11-03       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.